SneakPeek is the only provider of an arm-based, closed system like Snap, which keeps contamination and inconclusive rates extremely low.
LA JOLLA, Calif. (PRWEB) January 12, 2022
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 1,500 distributors of its SneakPeek Clinical test across the US, UK, and Canada. The rate of signup accelerated when the company added SneakPeek Snap to its clinical offerings.
“Our clinical product used to require phlebotomy resources,” says Gateway Genomics CEO, Chris Jacob. “We launched SneakPeek Snap direct-to-consumer on our website in June, and then began offering it to our partners in August, as well as new clinical locations. The benefits of Snap over phlebotomy immediately became clear: reduced cost and the ability to schedule a client any time the clinic was open instead of being restricted by the availability of a phlebotomist. For our partners, it reduced logistics complexity, and for their clients, it reduced time to result and increased flexibility and ease.”
SneakPeek Snap is the first and only self-administered push-button microneedle device that makes it easy for parents to learn the gender of their babies with no more fingersticks or large needles. The kit can be purchased online through the SneakPeek website or at a clinical location. While clinical providers help clients take the test, the self-contained nature of the Snap device makes it very easy to administer, with 90% of users calling it “easy to use” in a recent published study. In the same study, 90% of users found Snap to be “painless.”
“It provides an alternative option for clients who are fearful of visible needles, who want a proven pain-free method,” continues Mr. Jacob. “SneakPeek is the only provider of an arm-based, closed system like Snap, which keeps contamination and inconclusive rates extremely low. That combined with the many peer-reviewed publications supporting the accuracy of our gender test makes SneakPeek the preferred fetal sex test of our clinical partners. For this product, accuracy is king, and we’re dedicated to making the stats behind our products transparent with an extensive set of peer-reviewed studies.”
The SneakPeek Snap kit is stocked at all participating clinical locations, and clients can walk in to purchase and use the product any time the provider is open, increasing convenience and reducing time to learn fetal sex. The device is easily administered by either the client or the clinical provider by placing it on the upper arm and pushing a button, collecting the blood sample in 1 to 4 minutes. When SneakPeek Snap is removed from the arm, the tube is separated from the device, capped, and readied for mailing, with results to the customer as soon as next day.
In 2021, Gateway Genomics ranked #601 in the Inc. 5000 list of fastest-growing private companies in the U.S., #22 in the Health sector. In 2021’s Inc. 5000 California list, the company was ranked the 56th fastest-growing private company in the state, and #6 in the Health sector. Gateway Genomics’ principal product, SneakPeek Gender, is an easy-to-use DNA test that lets parents know the fetal sex of their babies as early as 7 weeks into pregnancy, with 99.9% accuracy.
About Gateway Genomics
Gateway Genomics is a personal genomics company with the mission to develop accurate, innovative, prenatal and pediatric tests that give families insight into the health and development of their children. Since inception, more than 500,000 SneakPeek DNA tests have been provided to help new parents bond with and learn about their babies, make plans, and connect with friends and family around them. Gateway Genomics is located in La Jolla, CA.